Development of novel vaccines against human cytomegalovirus

Figures & data

Table 1. Novel HCMV vaccine candidates.

Vaccine name	Design	Manufacture	Status	Key immunological principle of protection	References
Chiron gB	Recombinant protein furin cleavage site mutation	Chiron/Sanofi	Phase II clinical trial	Antibodies to gB, mainly autologous neutralizing antibody, possibly antibody-dependent cell-mediated phagocytosis	^[Citation24,Citation50-Citation52]
Trimeric HCMV gB	Recombinant protein (Gly4Ser)3 linker inserted in furin cleavage site	USUHS	Preclinical study	Antibodies to gB, high-titer cross-strain neutralizing antibody	^[Citation53]
Pentameric complex	Recombinant protein	Switzerland City of Hope	Preclinical study	Antibodies to pentameric complex	^[Citation54,Citation55]
DISC HCMV vaccine	Live attenuated replication defective HCMV	Merck	Phase I clinical trial	Humoral and T cell-mediated immune responses	^[Citation56]
MVA-vectored HCMV vaccine	Modified vaccinia virus Ankara expressing gB, pentameric complex pp65, IE1, and/or IE2	City of Hope	Phase II clinical trial	Antibodies to gB and pentameric complex, T-cell response to pp65, IE1, and IE2	^[Citation55,Citation57-Citation59]
eVLP HCMV vaccine	Enveloped virus-like particles with gB or pentameric complex expressed on surface	VBI Pfizer	Phase I clinical trial preclinical study	Antibodies to gB antibodies and T-cell response to gB, pentameric compex	^[Citation60-Citation62]
RNA HCMV vaccine	mRNA platform encoding gB, pp65, IE1, or pentameric complex	Novatis Moderna	Preclinical study Preclinical study	Antibodies to gB, T-cell-response to pp65, IE antibodies to gB and pentameric complex, T-cell response to pp65, gB, pentameric complex	^[Citation63,Citation64]

Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, Corey L, Hill J, Davis E, Flanigan C, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191–99. doi:10.1056/NEJMoa0804749. PubMed PMID: 19297572; PubMed Central PMCID: PMCPMC2753425.

 PubMed Web of Science ®Google Scholar

Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O’Beirne J, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256–63. doi:10.1016/S0140-6736(11)60136-0. PubMed PMID: 21481708; PubMed Central PMCID: PMCPMC3075549.

 PubMed Web of Science ®Google Scholar

Nelson CS, Huffman T, Jenks JA, Cisneros de la Rosa E, Xie G, Vandergrift N, Pass RF, Pollara J, Permar SR. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018;115(24):6267–72. doi:10.1073/pnas.1800177115. PubMed PMID: 29712861; PubMed Central PMCID: PMCPMC6004431.

 PubMed Web of Science ®Google Scholar

Cui X, Cao Z, Wang S, Lee RB, Wang X, Murata H, Adler SP, McVoy MA, Snapper CM. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response. Vaccine. 2018;36(37):5580–90. doi:10.1016/j.vaccine.2018.07.056. PubMed PMID: 30082162.

 PubMed Web of Science ®Google Scholar

Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S, Preite S, Fuschillo D, Percivalle E, Sallusto F, et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A. 2014;111(50):17965–70. doi:10.1073/pnas.1415310111. PubMed PMID: 25453106; PubMed Central PMCID: PMCPMC4273412.

 PubMed Web of Science ®Google Scholar

Chiuppesi F, Wussow F, Scharf L, Contreras H, Gao H, Meng Z, Nguyen J, Barry PA, Bjorkman PJ, Diamond DJ, et al. Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice. PLoS One. 2017;12(8):e0183377. doi:10.1371/journal.pone.0183377. PubMed PMID: 28813507; PubMed Central PMCID: PMCPMC5558987.

 PubMed Web of Science ®Google Scholar

Wang D, Freed DC, He X, Li F, Tang A, Cox KS, Dubey SA, Cole S, Medi MB, Liu Y, et al. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Sci Transl Med. 2016;8(362):362ra145. doi:10.1126/scitranslmed.aaf9387. PubMed PMID: 27797961.

 PubMed Web of Science ®Google Scholar

Link EK, Brandmüller C, Suezer Y, Ameres S, Volz A, Moosmann A, Sutter G, Lehmann MH. A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells. Vaccine. 2017;35(38):5131–39. doi:10.1016/j.vaccine.2017.08.019. PubMed PMID: 28818566.

 PubMed Web of Science ®Google Scholar

Chiuppesi F, Nguyen J, Park S, Contreras H, Kha M, Meng Z, Yekwa E, Barrot L, Barron S, Vallve A, et al. Multiantigenic modified vaccinia virus ankara vaccine vectors to elicit potent humoral and cellular immune reponses against human cytomegalovirus in mice. J Virol. 2018;92(19). doi:10.1128/JVI.01012-18. PubMed PMID: 30045984; PubMed Central PMCID: PMCPMC6146800.

 PubMed Web of Science ®Google Scholar

Kirchmeier M, Fluckiger A-C, Soare C, Bozic J, Ontsouka B, Ahmed T, Diress A, Pereira L, Schödel F, Plotkin S, et al. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol. 2014;21(2):174–80. doi:10.1128/CVI.00662-13. PubMed PMID: 24334684; PubMed Central PMCID: PMCPMC3910943.

 PubMed Web of Science ®Google Scholar

Cytomegalovirus infection: advancing strategies for prevention and treatment [Internet]. NIAID/NICHD/FDA meeting, Bethesda (MD); 2018 Sep 4–6.

 Google Scholar

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109(36):14604–09. doi:10.1073/pnas.1209367109. PubMed PMID: 22908294; PubMed Central PMCID: PMCPMC3437863.

 PubMed Web of Science ®Google Scholar

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22(12):2118–29. doi:10.1038/mt.2014.133. PubMed PMID: 25027661; PubMed Central PMCID: PMCPMC4429691.

 PubMed Web of Science ®Google Scholar